Advanced Medical Solutions Group (LON:AMS) Announces Quarterly Earnings Results

Advanced Medical Solutions Group (LON:AMS) released its earnings results on Thursday. The company reported GBX 10.65 ($0.14) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Advanced Medical Solutions Group had a return on equity of 4.57% and a net margin of 8.49%.

Advanced Medical Solutions Group Trading Down 1.7 %

Shares of LON:AMS traded down GBX 3.50 ($0.05) during mid-day trading on Friday, hitting GBX 201 ($2.61). The company had a trading volume of 1,740,479 shares, compared to its average volume of 862,780. The company has a market capitalization of £434.01 million, a PE ratio of 38.95, a price-to-earnings-growth ratio of 5.00 and a beta of 0.74. Advanced Medical Solutions Group has a one year low of GBX 176.60 ($2.29) and a one year high of GBX 275.83 ($3.58). The firm has a fifty day moving average price of GBX 211.58 and a 200 day moving average price of GBX 212.49. The company has a debt-to-equity ratio of 37.01, a current ratio of 8.39 and a quick ratio of 4.58.

Advanced Medical Solutions Group Increases Dividend

The firm also recently declared a dividend, which will be paid on Friday, June 20th. Shareholders of record on Thursday, May 29th will be paid a GBX 1.83 ($0.02) dividend. The ex-dividend date is Thursday, May 29th. This is a positive change from Advanced Medical Solutions Group’s previous dividend of $0.77. This represents a yield of 0.89%. Advanced Medical Solutions Group’s payout ratio is 38.76%.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank reaffirmed a “buy” rating and set a GBX 300 ($3.89) target price on shares of Advanced Medical Solutions Group in a research note on Wednesday.

About Advanced Medical Solutions Group

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, and Seal-G®.